The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. 1999

T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
Department of Cell Genetics, Sasaki Institute, 2-2, Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan. toikawa@goldfish sasaki.or.jp

The PU.1 gene encodes an Ets family transcription factor which controls expression of many B cell- and macrophage-specific genes. Expression of the gene is critical for development of lymphoid and myeloid cell lineages, since PU.1-deficient mice exhibit defects in the development of these cell lineages. The PU.1 gene is identical to the Spi-1 gene isolated from common proviral integration sites in Friend virus-induced murine erythroleukemia (MEL), and deregulated expression of the gene is believed to be an essential step of the disease. We recently demonstrated that overexpression of PU.1 inhibits erythroid differentiation of MEL cells induced with the differentiating agent DMSO. We also noticed unexpectedly that overexpression of PU.1 together with DMSO induces marked growth arrest and apoptosis in MEL cells, supporting the notion that some oncogenes induce growth inhibition and apoptosis rather than cell proliferation and transformation under specific circumstances as shown with the c-myc gene. In this review, the role of PU.1 in hematopoietic cell differentiation, proliferation and apoptosis is described and the possible molecular mechanisms of PU.1-induced effects in MEL cells are discussed.

UI MeSH Term Description Entries
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015534 Trans-Activators Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins. Nuclear Trans-Acting Factor,Trans-Acting Factors,Trans-Acting Factor,Trans-Activator,Transactivator,Transactivators,Factor, Nuclear Trans-Acting,Factor, Trans-Acting,Factors, Trans-Acting,Nuclear Trans Acting Factor,Trans Acting Factor,Trans Acting Factors,Trans Activator,Trans Activators,Trans-Acting Factor, Nuclear
D016259 Genes, myc Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8. L-myc Genes,N-myc Genes,c-myc Genes,myc Genes,v-myc Genes,L-myc Proto-Oncogenes,N-myc Proto-Oncogenes,c-myc Proto-Oncogenes,myc Oncogene,v-myc Oncogenes,Gene, L-myc,Gene, N-myc,Gene, c-myc,Gene, myc,Gene, v-myc,Genes, L-myc,Genes, N-myc,Genes, c-myc,Genes, v-myc,L myc Genes,L myc Proto Oncogenes,L-myc Gene,L-myc Proto-Oncogene,N myc Genes,N myc Proto Oncogenes,N-myc Gene,N-myc Proto-Oncogene,Oncogene, myc,Oncogene, v-myc,Oncogenes, myc,Oncogenes, v-myc,Proto-Oncogene, L-myc,Proto-Oncogene, N-myc,Proto-Oncogene, c-myc,Proto-Oncogenes, L-myc,Proto-Oncogenes, N-myc,Proto-Oncogenes, c-myc,c myc Genes,c myc Proto Oncogenes,c-myc Gene,c-myc Proto-Oncogene,myc Gene,myc Oncogenes,v myc Genes,v myc Oncogenes,v-myc Gene,v-myc Oncogene

Related Publications

T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
September 2017, The Journal of biological chemistry,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
December 2004, Blood,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
September 1993, Molecular and cellular biology,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
December 2020, International journal of molecular medicine,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
August 2006, Stem cells and development,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
March 1998, The Journal of biological chemistry,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
January 2014, Nucleic acids research,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
November 1993, Blood,
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
September 2016, Journal of immunology (Baltimore, Md. : 1950),
T Oikawa, and T Yamada, and F Kihara-Negishi, and H Yamamoto, and N Kondoh, and Y Hitomi, and Y Hashimoto
April 1990, Cell,
Copied contents to your clipboard!